CD4 and neoplasm: Flow cytometry (Fig. 6a, b, e, and f) showed a considerable antitumor response after KN046 therapy, with the percentages of CD4+ T cells (12.21% vs. 9.05%) and CD8+ T cells (9.01% vs. 7.40%) in the tumor increasing after treatment with [131I]-KN046 versus KN046 alone.